Returns From Sanofi Consumer Expansion Could Point To More
The French pharma's strategy of driving consumer health business growth by expanding the product lineup played out during the first quarter with the launch of OTC switch Xyzal Allergy and with further integration of OTC drug and vitamin brands recently acquired from Boehringer Ingelheim.
You may also be interested in...
Sanofi consumer products head Alan Main says BI's brands will "lift Sanofi into leadership positions in attractive OTC categories, namely the vitamins and minerals supplements market, digestive products, cough and cold as well as pain medications."
FDA approval of Xyzal Allergy 24HR enables Sanofi to compete in the once-daily OTC pediatric antihistamine space in the US.
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.